Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases

Authors


  • Funding sources
    No external funding.

  • Conflicts of interest
    A.de.S., T.A-S. and S.M.R.: nothing to declare. D.F.: Amgen: consulting, advisory board participant; Centocor/J&J: consulting fees, advisory board participant. B.E.S.: Amgen: speaking fees, consulting fees, advisory board participant; Abbott: speaking fees, consulting fees, advisory board participant; Centocor/J&J: speaking fees, consulting fees, advisory board participant, receipt of fellowship grant; Galderma: consulting fees, advisory board participant; Stiefel: advisory board participant.

A. de Souza.
E-mail: aieska@yahoo.com

Summary

Psoriasis is a chronic inflammatory skin condition, characterized by T-helper (Th) 1 and Th17 cell activation. Ustekinumab is a fully human immunoglobulin G1κ monoclonal antibody that targets the common p40 subunit that is shared by both interleukin (IL)-12 and IL-23, consequently inhibiting T-cell differentiation along both Th1 and Th17 pathways. This is a report of two patients who developed psoriatic arthritis during ustekinumab treatment for psoriasis. Neither patient had a personal or family history of arthritis.

Ancillary